Vistin Pharma ASA reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was NOK 119.94 million compared to NOK 91.71 million a year ago. Net income was NOK 23.49 million compared to net loss of NOK 6.7 million a year ago. Basic earnings per share from continuing operations was NOK 0.53 compared to basic loss per share from continuing operations of NOK 0.15 a year ago.
For the nine months, sales was NOK 327.61 million compared to NOK 193.92 million a year ago. Net income was NOK 27.61 million compared to net loss of NOK 21.61 million a year ago. Basic earnings per share from continuing operations was NOK 0.62 compared to basic loss per share from continuing operations of NOK 0.49 a year ago.